Gabriel Alvarez
Psychiatric/Mental Health · Longwood, FLNPI 1144576190
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Alkermes, Inc. at 56.4% of the total. Reporting peaked in 2023 at $25,439 and has fallen 93.4% since, to $1,680 in 2025. Among psychiatric/mental health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 465 payments — averaging $79.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$21K
- AbbVie$11K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$636
- Axsome Therapeutics, Inc.$580
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$499
- plus $2K from 17 others
What the payments were for
- Consulting fees$2,8008%
- Speaking & faculty fees$20,88356%
- Travel & lodging$3,3399%
- Food & beverage$10,00327%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 99 | $20,913 |
| AbbVie | 86 | $10,777 |
| Otsuka America Pharmaceutical, Inc. | 65 | $1,215 |
| Johnson & Johnson | 29 | $636 |
| Axsome Therapeutics, Inc. | 21 | $580 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $499 |
| Vanda Pharmaceuticals Inc. | 23 | $402 |
| Neurocrine Biosciences, Inc. | 25 | $375 |
| Sunovion Pharmaceuticals Inc. | 22 | $329 |
| Teva Pharmaceuticals USA, Inc. | 9 | $279 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $197 |
| Collegium Pharmaceutical, Inc. | 6 | $177 |
| Corium, LLC | 8 | $145 |
| Neos Therapeutics, LP | 4 | $75 |
| Bausch Health US, LLC | 4 | $72 |
| Noven Therapeutics, LLC | 4 | $70 |
| Lundbeck LLC | 4 | $62 |
| Supernus Pharmaceuticals, Inc. | 4 | $61 |
| E.r. Squibb & Sons, L.L.C. | 3 | $53 |
| USWM, LLC | 2 | $44 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $41 |
| Indivior Inc. | 2 | $35 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$73,691
- VRAYLAR$9,496
- ARISTADA$1,953
- ARISTADA INITIO$488
- REXULTI$331
- Auvelity$244
- AUSTEDO$147
- JORNAY PM$116
- INVEGA SUSTENNA$109
How this compares
$37,050 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buspirone Hcl | 13 | $456 |
| Mirtazapine | 11 | $282 |
| Carbamazepine | 12 | $277 |
| Sertraline Hcl | 13 | $177 |
| Bupropion XlBupropion Hcl | 14 | $172 |
| Clonazepam | 53 | $163 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 13 | $157 |
| Methylphenidate Hcl | 13 | $128 |
| Paroxetine Hcl | 11 | $71 |
| Prazosin Hcl | 11 | $60 |
| Fluoxetine Hcl | 11 | $27 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Longwood
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
- Carolann BrooksCelebration$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.